IDH1 and central nervous system cancer: We first tested the effect of NSC185058, which targets ATG4b (Fig. 8k).53 Treatment with NSC185058 or irradiation alone decreased IDH1 glioma cells viability compared to vehicle (Figs. 8l–n).